Real-World Experience on the Use of COVID-19 Vaccination in Multiple Sclerosis Patients Treated with Cladribine Tablets Participating in the ADVEVA® Patient Support Program within the Gulf and Latin American Regions

BACKGROUND: National Multiple Sclerosis Society and other international guidelines suggest that full COVID-19 vaccination status should be completed two to four weeks before starting Year 2 of treatment with cladribine tablets (CladT). CladT is administered twice over two years, Year 1 and Year 2. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodas, María Isabel Zuluaga, Negrotto, Laura, Deramo, Mariana, Inshasi, Jihad, Boshra, Amir, Youssef, Joseph, De Souza, Sabrina, Cantogno, Elisabetta Verdun Di, Boumenna, Tahani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2023
Materias:
Msc2022-a-2065
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065167/
http://dx.doi.org/10.1016/j.msard.2022.104351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065167/
http://dx.doi.org/10.1016/j.msard.2022.104351

Ejemplares similares